Morphologic and Molecular Evolutionary Pathways of Low Nuclear Grade Invasive Breast Cancers and Their Putative Precursor Lesions: Further Evidence to Support the Concept of Low Nuclear Grade Breast Neoplasia Family

We have previously provided evidence showing an association between some precursor lesions with low nuclear grade breast carcinomas (LNGBCs). In this study, further immunophenotypic support to our proposed route of pathogenesis of LNGBC and their precursor lesions was provided. Precursor lesions including columnar cell lesions, atypical ductal hyperplasia, ductal carcinoma in situ, usual epithelial hyperplasia, and lobular neoplasia were compared with matching “morphologically normal” terminal lobular duct units and matching invasive carcinoma. The epithelial cells in the putative precursor flat epithelial atypia, atypical ductal hyperplasia, lobular neoplasia, ductal carcinoma in situ lesions, and their coexisting LNGBC were negative for basal and myoepithelial markers, but positive for CK19/18/8, estrogen receptor (ER)-α, Bcl-2, and cyclin D1. The ER-α/ER-β expression ratio increased during carcinogenesis, as did expression of cyclin D1 and Bcl-2. p53 immunopositivity was found 3% in LNGBC versus 43% in high nuclear grade breast carcinoma (HNGBC), whereas ataxia telangiectasia mutated expression was absent or reduced in 22% of LNGBC versus 53% of HNGBC cases. In summary, our findings support the concept that flat epithelial atypia is the earliest morphologically identifiable nonobligate precursor lesion of LNGBC. These may represent a family of precursor, in situ and invasive neoplastic lesions belonging to the luminal “A” subclass of breast cancer. The balance between ER-α and ER-β expression may be important in driving cyclin D-1 and Bcl-2 expression. Ataxia telangiectasia mutated may be one of the alternative regulatory mechanisms to TP53 mutation or dysfunction in low-grade and high-grade breast carcinoma. Our findings support the concept that progression of LNGBC to HNGBC (basal-like or HER2+) phenotype is an unlikely biologic phenomenon.

[1]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[2]  I. Ellis,et al.  High Frequency of Coexistence of Columnar Cell Lesions, Lobular Neoplasia, and Low Grade Ductal Carcinoma In Situ With Invasive Tubular Carcinoma and Invasive Lobular Carcinoma , 2007, The American journal of surgical pathology.

[3]  A. Ashworth,et al.  A mouse model of basal‐like breast carcinoma with metaplastic elements , 2007, The Journal of pathology.

[4]  G. Dontu,et al.  Stem cells in mammary development and carcinogenesis , 2007, Stem Cell Reviews.

[5]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[6]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[7]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[8]  E. Campo,et al.  ATM gene expression is associated with differentiation and angiogenesis in infiltrating breast carcinomas. , 2006, Histology and histopathology.

[9]  Sunil R Lakhani,et al.  The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. , 2005, Pathology, research and practice.

[10]  J. Reis-Filho.  Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005; 206: 451–457 , 2005, The Journal of pathology.

[11]  R. Elledge,et al.  Premalignant and In Situ Breast Disease: Biology and Clinical Implications , 2005, Annals of Internal Medicine.

[12]  J. Deschênes,et al.  Overexpression of Estrogen Receptors in Columnar Cell Change and in Unfolding Breast Lobules , 2005, The breast journal.

[13]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[14]  P. V. van Diest,et al.  The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.

[15]  I. Ellis,et al.  Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?: A Morphological and Molecular Analysis , 2005, The American journal of surgical pathology.

[16]  D. Ross,et al.  Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer , 2005, Breast Cancer Research.

[17]  Fariba Behbod,et al.  Will cancer stem cells provide new therapeutic targets? , 2005, Carcinogenesis.

[18]  Daniel Birnbaum,et al.  Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. , 2005, Cancer research.

[19]  J. Russo,et al.  Breast differentiation and its implication in cancer prevention. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[21]  J. Gustafsson,et al.  Differential regulation of Estrogen Receptor (ER)α and ERβ in primate mammary gland , 2005 .

[22]  J. Gustafsson,et al.  Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  M. J. van de Vijver,et al.  Different mechanisms of chromosome 16 loss of heterozygosity in well‐ versus poorly differentiated ductal breast cancer , 2004, Genes, chromosomes & cancer.

[24]  P. Pujol,et al.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. , 2004, Endocrine-related cancer.

[25]  G. Dontu,et al.  Breast cancer, stem/progenitor cells and the estrogen receptor , 2004, Trends in Endocrinology & Metabolism.

[26]  S. Ding,et al.  Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade , 2004, British Journal of Cancer.

[27]  E. Garrido,et al.  Bcl-2 protein in normal, hyperplastic and neoplastic breast tissues. A metabolite of the putative stem-cell subpopulation of the mammary gland. , 2004, Histology and histopathology.

[28]  G. Firestone,et al.  Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest , 2004, Cancer Research.

[29]  C. Eaves,et al.  Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue , 2001, Breast Cancer Research and Treatment.

[30]  A. Shaaban,et al.  Declining Estrogen Receptor-&bgr; Expression Defines Malignant Progression of Human Breast Neoplasia , 2003, The American journal of surgical pathology.

[31]  A. Vincent-Salomon,et al.  Columnar Cell Lesions of the Breast , 2003, Advances in anatomic pathology.

[32]  C. Croce,et al.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. , 2003, Cancer research.

[33]  S. Lakhani,et al.  Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast , 2003, The Journal of pathology.

[34]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[35]  J. Mosquera,et al.  Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas , 2002, The Journal of pathology.

[36]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[37]  T. Crook,et al.  The p53 pathway in breast cancer , 2002, Breast Cancer Research.

[38]  Chris Albanese,et al.  Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. , 2002, The Journal of biological chemistry.

[39]  P. V. van Diest,et al.  Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high‐molecular‐weight cytokeratin expression patterns , 2001, The Journal of pathology.

[40]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Devries,et al.  Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  P. V. van Diest,et al.  Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution , 2001, The Journal of pathology.

[43]  J. Gustafsson,et al.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. , 2001, Cancer research.

[44]  Y. Ko,et al.  Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status , 2001, Pathology international.

[45]  Y. Miyoshi,et al.  Quantitative analysis of estrogen receptor‐α and ‐β messenger RNA expression in breast carcinoma by real‐time polymerase chain reaction , 2000 .

[46]  H. Höfler,et al.  Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[47]  Y. Miyoshi,et al.  Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. , 2000, Cancer.

[48]  Qifeng Yang,et al.  Expression of Bcl‐2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma , 1999, Pathology international.

[49]  R. Sutherland,et al.  Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  E. Lane,et al.  The development of epithelial phenotypes in the human fetal and infant breast , 1998, The Journal of pathology.

[51]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[52]  I. Ellis,et al.  High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. , 1996, Cancer research.